The global meningitis vaccines market reached USD million in 2022 and is projected to witness lucrative growth by reaching up to USD million by 2030. The market is growing at a CAGR of 9.6% during the forecast period (2023-2030). Meningitis is inflammation of the meninges, the lining of the brain, and the spinal cord.
It is most commonly caused by bacterial, viral, or fungal infections. Symptoms progress rapidly and rapidly deteriorate a person's health. Viral infections are rarely life threatening. Most people recover without noticeable sequelae, but for some it can lead to long-term, life-changing illness. Severe cases of meningitis are most often caused by bacterial infections. Vaccination of the most at-risk populations develops protection against some of the most common causes of disease and provides a safe way to reduce the risk of spreading infection within communities.
Metrics |
Details |
CAGR |
9.6% |
Size Available for Years |
2021-2030 |
Forecast Period |
2023-2030 |
Data Availability |
Value (US$) and Volume (Tons) |
Segments Covered |
Vaccine, Age Group, End user, Distribution Channel and Region |
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
Fastest Growing Region |
Asia-Pacific |
Largest Region |
North America |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
The increasing FDA approvals for the vaccine by the key market players are the factors to drive the market growth.
On October 17, 2022, GSK plc announced that the US Food and Drug Administration (FDA) approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation now comes in a ready-to-use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation will initially be available to US federal customers, with broader availability anticipated in mid-2023.
Additionally, On December 29, 2022, Pfizer PFE announced that the FDA has accepted its biologics license application (BLA) for its pentavalent meningococcal vaccine candidate (MenABCWY). The BLA seeks approval of MenABCWY for the prevention of meningococcal disease caused by the five meningococcal serogroups that cause the majority of invasive meningococcal disease: serogroups A, B, C, W, and Y. As a result of the aforementioned factors, the market is expected to drive during the forecast period.
The high cost and side effects of vaccines are factors hindering the market growth.
According to the Pan American Health Organization, healthcare costs for meningococcal disease range from $4,500 to $6,500 per patient, with outbreak control costs exceeding $3 million (USD) in some areas. In addition, meningococcal vaccination can rarely cause severe allergic reactions. Hoarseness, wheezing, and trouble breathing or swallowing are all symptoms. Therefore, the above factors are expected to hamper the market during the forecast period.
The global meningitis vaccines market is segmented based on vaccine, age group, end user, distribution channel and region.
The pneumococcal vaccines segment will be dominated by market players due to its benefits, product launches, and clinical trials during the forecast period.
Pneumococcal infection is a disease caused by Streptococcus pneumoniae bacteria. Vaccines help prevent pneumococcal infections. Two pneumococcal vaccines are available in the United States. Pneumococcal conjugate vaccine (PCV13, PCV15, PCV20) and pneumococcal polysaccharide vaccine (PPSV23). For instance, Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) from Pfizer is approved for active immunization in adults 18 years of age and older to prevent pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Prevnar 20 is approved under accelerated approval to prevent pneumonia caused by S. pneumoniae serotypes 8, 10, 11A, 12F, 15B, 22F, and 33F. Furthermore, the increasing clinical trials and product launches by the market players are the factors to drive the market in the forecast period. For instance, On August 12, 2022, Pfizer Inc. announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population. Above mentioned factors help the product segment to dominate the market.
Source: DataM Intelligence Analysis (2023)
Rising awareness of pneumococcal vaccines, project launches, and clinical trials in the region are the factors to drive regional growth.
North America region accounted for the largest market share in the forecast period. The regional growth is driven by rising awareness of pneumococcal vaccines, project launches, and clinical trials. For instance, the Meningitis B Action Project is a joint initiative by the Kimberly Coffey Foundation and The Emily Stillman Foundation. On January 26, 2023, the Meningitis B Action Project launched the Meningitis B Action Project Dinner Club. The Dinner Club is intended to foster open discussion about the barriers to meningococcal meningitis prevention and how the projects can work together to overcome those obstacles. The Meningitis B Action Project Dinner Club's first stop was Salt Lake City, Utah. Furthermore, the above-stated factors depict the North American region's dominance globally.
Source: DataM Intelligence Analysis (2023)
The major global players include GlaxoSmithKline plc., Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Novartis AG, Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Vacsera, Zhi Fei Biological, BIO MED, CanSinoBIO and Eubiologics Co., Ltd.
Why Purchase the Report?
The global meningitis vaccines market report would provide approximately 92 tables, 108 figures and 195 Pages.
Target Audience 2023